Connor, Clark & Lunn Investment Management (CC&L)
RNAC icon

Connor, Clark & Lunn Investment Management (CC&L)’s Cartesian Therapeutics RNAC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-908
Closed -$30.8K – 1418
2022
Q4 		$30.8K Sell
908
-3,987
-81% -$170K ﹤0.01% 1160
2022
Q3 		$241K Sell
4,895
-401
-8% -$22K ﹤0.01% 960
2022
Q2 		$208K Sell
5,296
-6,496
-55% -$193K ﹤0.01% 929
2022
Q1 		$435K Sell
11,792
-2,618
-18% -$164K ﹤0.01% 804
2021
Q4 		$1.41M Buy
14,410
+75
+0.5% +$8.07K 0.01% 613
2021
Q3 		$1.79M Buy
14,335
+6,962
+94% +$841K 0.01% 543
2021
Q2 		$925K Buy
7,373
+4,710
+177% +$561K ﹤0.01% 681
2021
Q1 		$361K Buy
2,663
+2,023
+316% +$251K ﹤0.01% 837
2020
Q4 		$58K Buy
+640
New +$55.5K ﹤0.01% 874
2020
Q3 		– Sell
-4,413
Closed -$376K – 1097
2020
Q2 		$376K Buy
+4,413
New +$400K ﹤0.01% 803

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RNAC Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 908 shares — an estimated $30.8K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RNAC in Q2 2020 and held it in 10 quarters. The position peaked at $1.79M in Q3 2021. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 908 Cartesian Therapeutics shares in Q1 2023, an estimated $30.8K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Cartesian Therapeutics in Q2 2020 and held it in 10 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Cartesian Therapeutics position peaked at $1.79M in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.